Quantcast

Latest Actavis Stories

2014-05-23 08:24:32

CHAGRIN FALLS, Ohio, May 23, 2014 /PRNewswire/ -- EnzymeBioSystems (OTCBB: ENZB) (OTCQB: ENZB), announces the appointment of Gary Rojewski as its new CEO, effective June 2, 2014. Mr. Rojewski will be responsible for leading and managing EnzymeBioSystems' business operations, including regulatory affairs with government agencies. Mr. Rojewski has 29-years experience in the pharmaceutical industry. During that time he has worked for Procter and Gamble Pharmaceuticals (PG), Warner...

2014-05-22 08:30:15

DUBLIN, May 22, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that, subject to the close of its pending acquisition (the "Acquisition") of Forest Laboratories, Inc. (NYSE: FRX), it is offering to guarantee certain of Forest's outstanding debt securities in exchange for the elimination of the existing registration rights obligations with respect to those outstanding debt securities. Forest is soliciting consents ("Consents") from holders of its securities listed in the...

2014-05-21 08:29:22

DUBLIN, May 21, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/78cbh2/global_pva_drugs) has announced the addition of the "Global PVA Drugs Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Vaginal atrophy is defined as a decrease in estrogen production. Less estrogen leads to thinning, drying, and decreased elasticity of the vaginal tissues. PVA is defined as the decrease in estrogen after menopause. Up to...

2014-05-15 08:33:22

DUBLIN, May 15, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has reached an agreement with Janssen Pharmaceuticals, Inc. (JPI) to continue supplying the authorized generic version of JPI's Concerta(®) (methylphenidate hydrochloride extended-release tablets). Under the terms of the extended exclusive supply and distribution agreement -- which was first agreed to by the companies in November 2010 and due to expire on December 31, 2014 -- JPI will continue to...

2014-05-14 08:31:00

- Paul Bisaro to Assume Newly Created Role as Executive Chairman - DUBLIN, May 14, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced the proposed senior management team that will lead the specialty pharmaceutical company pending the successful close of the acquisition of Forest Laboratories, Inc., which is anticipated at mid-year. Following the close, Paul Bisaro, Chairman and Chief Executive Officer of Actavis, will become Executive Chairman. Brent Saunders,...

2014-05-13 16:29:25

DUBLIN, May 13, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Mallinckrodt Inc.'s Exalgo(®) (Hydromorphone Hydrochloride Extended-release Tablets 8 mg, 12 mg and 16 mg). Actavis intends to begin shipping its product shortly and believes that, under applicable Hatch Waxman rules, it may be entitled to marketing exclusivity....

2014-05-13 16:29:15

DUBLIN, May 13, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Paul Bisaro, Chairman and CEO of Actavis, will provide an overview and update of the Company's business at the Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014 in New York City. The presentation will take place on Thursday, May 29, 2014 at 10:00 a.m. Eastern Time at the Waldorf-Astoria Hotel, 301 Park Avenue, New York, NY. To...

2014-05-12 16:29:38

LAVAL, Quebec, May 12, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that certain of its subsidiaries have entered into settlement agreements with affiliates of Actavis plc related to Actavis' generic versions of Acanya® Gel, 1.2%/2.5%, and Tiazac ® XC. Valeant's subsidiaries, Dow Pharmaceuticals Sciences, Inc. and Valeant Pharmaceuticals North America LLC, and Actavis' subsidiary, Watson Laboratories, Inc., entered into...

2014-05-12 08:31:42

DUBLIN, May 12, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Valeant Pharmaceuticals International to settle all outstanding patent litigation related to Actavis' generic version of Acanya(® )(clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%. Acanya(®) Gel is a lincosamide antibiotic and benzoyl peroxide indicated for the topical treatment of acne vulgaris. Under the terms of the agreement, Valeant will grant...

2014-05-09 08:26:36

ST. LOUIS, May 9, 2014 /PRNewswire-USNewswire/ -- Today, K-V Pharmaceutical Company ("KV") announced that Paul Williams - a seasoned executive with extensive experience in both neonatal health and the bio-pharmaceuticals business - has joined the company to lead its Women's Healthcare Division. KV recently underwent a broader reorganization of the Company's operations, creating two new business units: the Women's Healthcare Division, led by Williams, and the Maternal Health Division, led by...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.